aspirin has been researched along with eicosapentaenoic acid in 78 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (12.82) | 18.7374 |
| 1990's | 9 (11.54) | 18.2507 |
| 2000's | 22 (28.21) | 29.6817 |
| 2010's | 28 (35.90) | 24.3611 |
| 2020's | 9 (11.54) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Gordge, MP; Neild, GH; Rylance, PB | 1 |
| Force, T; Hibberd, P; Leaf, A; Lorenz, R; Milani, R; Uedelhoven, W; Weber, P | 1 |
| Ablett, MB; Ilsley, CD; Nye, ER; Robertson, MC; Sutherland, WH | 1 |
| Chetty, N; Kinlough-Rathbone, RL; Mustard, JF; Packham, MA; Vickers, JD | 1 |
| Krahenbuhl, B | 1 |
| Campbell, WB; Dehmer, GJ; Eichhorn, EJ; Jennings, L; Popma, JJ; Prewitt, JB; Schmitz, JM; van den Berg, EK; Willerson, JT | 1 |
| Hashimoto, Y; Kato, H; Kawamura, M; Naito, C; Oka, H; Teramoto, T | 1 |
| Dyerberg, J; Høj Nielsen, A; Jørgensen, KA | 1 |
| Agusti-Vidal, A; Castillo, JA; Coronas, A; Ordinas, A; Picado, C; Pujades, M; Schinca, N | 1 |
| Gustafson, A; Thorngren, M | 1 |
| Jørgensen, KA | 1 |
| Gustafson, A; Thorngren, M; Wohlfart, G | 1 |
| Terada, H | 1 |
| Chen, LY; Lawson, DL; Mehta, JL | 1 |
| Bardos, P; Gruel, Y; Khalfoun, B; Lacord, M; Lebranchu, Y; Thibault, G | 1 |
| Currier, WW; Lee, M | 1 |
| Hirai, A; Saitoh, Y; Shiina, T; Tamura, Y; Terano, T | 1 |
| Anil, K; Jayadeep, A; Sudhakaran, PR | 1 |
| Abe, F; Abe, K; Ito, S; Omata, K; Yamada, M | 1 |
| Chiang, N; Clish, CB; Gronert, K; Serhan, CN; Takano, T | 1 |
| Brannon, J; Chiang, N; Clish, CB; Colgan, SP; Gronert, K; Serhan, CN | 1 |
| Engström, K; Saldeen, T; Wallin, R | 1 |
| Marchioli, R; Schweiger, C; Tavazzi, L; Valagussa, F | 1 |
| Arita, M; Gotlinger, K; Hong, S; Serhan, CN | 2 |
| Koven, WM; Nixon, O; Spanings, FA; Van Anholt, RD; Wendelaar Bonga, SE | 1 |
| Serhan, CN | 2 |
| Baggio, B; Calò, LA; Musacchio, E; Pagnin, E; Priante, G | 1 |
| Carta, G; Falciglia, K; Iovenitti, P | 1 |
| Arita, M; Blumberg, RS; Glickman, JN; Hong, S; Petasis, NA; Serhan, CN; Tjonahen, E; Yoshida, M | 1 |
| Arita, M; Clish, CB; Serhan, CN | 1 |
| Schwab, JM; Serhan, CN | 1 |
| Chiang, N; Serhan, CN | 1 |
| Gilroy, DW; Morris, T; Stables, M | 1 |
| Maillard, MH | 1 |
| Van Dyke, TE | 1 |
| Bria, P; Pomponi, M | 1 |
| Beller, E; Cass, A; Dogra, G; Hawley, C; Heritier, S; Irish, A; Kerr, P; Mori, T; Paul-Brent, PA; Polkinghorne, K; Robertson, A; Rosman, J; Starfield, M | 1 |
| Bannenberg, GL | 1 |
| Arita, M; Seki, H; Tani, Y | 1 |
| Dong, L; Noon, KR; Sharma, NP; Smith, WL; Yuan, C | 1 |
| Aboelsaad, N; Alshahat, M; Darweesh, M; El-Sharkawy, H; Eliwa, M; Hasturk, H; Kantarci, A; Van Dyke, TE | 1 |
| Conte, MS; Creager, MA; Ho, KJ; Kroemer, AH; Lancero, H; Owens, CD; Pande, R; Serhan, CN; Spite, M | 1 |
| Oh, SF; Pillai, PS; Recchiuti, A; Serhan, CN; Yang, R | 1 |
| Araki, H; Suemaru, K; Tanaka, A; Tanaka, M | 1 |
| Clifford, GM; Hull, MA; Loadman, PM; Logan, RF; Montgomery, AA; Rees, CJ; Sandell, AC; Whitham, D | 1 |
| Adachi, S; Hironaga, K; Hongo, H; Kozai, T; Matsukawa, R; Miura, S; Nozoe, M; Okabe, M; Osaka, K; Saku, K; Serikawa, T; Takesue, K; Tokutome, M; Yamamoto, Y; Yanagi, D; Yoshikawa, T | 1 |
| Chmiel, A; Gąsior, Z; Gieszczyk-Strózik, K; Haberka, M; Kyrcz-Krzemień, S; Lasota, B; Mizia, M; Mizia-Stec, K; Najda, J | 1 |
| Hosogoe, N; Ishikawa, S; Isshiki, T; Takada, K; Yokoyama, N | 1 |
| Arnardottir, HH; Colas, RA; Dalli, J; Serhan, CN; Shinohara, M | 1 |
| Abdolahi, A; Block, RC; Brenna, JT; Georas, SN; Lawrence, P; Mousa, SA; Phipps, RP; Tu, X | 1 |
| Badve, SV; Cass, A; Hawley, C; Heritier, S; Irish, AB; Kerr, PG; Mori, TA; Pascoe, E; Paul-Brent, PA; Polkinghorne, KR; Robertson, A; Seong, HL; Viecelli, AK | 1 |
| Badve, SV; Cass, A; Hawley, CM; Hooi, SL; Irish, AB; Johnson, DW; Kerr, PG; Mori, TA; Ong, ML; Pascoe, EM; Paul-Brent, PA; Polkinghorne, KR; Scaria, A; Viecelli, AK | 1 |
| Fortin, S; Hiram, R; Marouan, S; Morin, C; Rizcallah, E; Rousseau, E; Sirois, C; Sirois, M | 1 |
| Bhatt, AN; Das, UN; Dwarakanath, BS; Poorani, R | 1 |
| Arita, M; Hanafusa, N; Hayashi, M; Hirahashi, J; Hishikawa, K; Nangaku, M; Wada, T | 1 |
| Fischer, T | 1 |
| Barden, AE; Croft, KD; Mas, E; Mori, TA; Phillips, M | 1 |
| Chiang, N; Colas, RA; Dalli, J; Elajami, TK; Serhan, CN; Welty, FK | 1 |
| Das, UN | 1 |
| Abdolahi, A; Block, RC; Holub, A; Mousa, SA; Oda, MN; Tu, XM | 1 |
| Ando, H; Furuki, Y; Hagiwara, N; Ishida, I; Jujo, K; Nakabayashi, K; Saito, K; Shimizu, M | 1 |
| Dekker, E; Kaminski, MF | 1 |
| Clifford, G; Hepburn, T; Hull, MA; Loadman, PM; Logan, RF; Montgomery, AA; Rees, CJ; Shafayat, A; Sprange, K; Tan, W; Whitham, D; Williams, EA | 1 |
| Dickson, I | 1 |
| DeCensi, A; Gescher, A | 1 |
| Danış, N; Tekin, F | 1 |
| Banach, M; Bo, S; Marjaneh, RM; Paseban, M; Riahi, MM; Sahebkar, A | 1 |
| Arnwine, C; Lockwood, K; Magness, JW; Reinert, A | 1 |
| Campbell, JD; McQueen, RB; Ollendorf, DA; Pearson, SD; Synnott, PG | 1 |
| Abdolahi, A; Block, RC; Brenna, JT; Godugu, K; Holub, A; Mousa, S; Tu, XM | 1 |
| Coletta, PL; Hull, MA; Hutchinson, JM; Ingram, N; Loadman, PM; Marshall, C; Nicolaou, A; Perry, SL; Race, AD; Spencer, J; Volpato, M | 1 |
| Block, RC; Brenna, JT; Harris, WS; Holub, A; Mousa, S; Shearer, GC; Tintle, N; Tu, XM | 1 |
| Block, RC; Mousa, SA; Wang, IE; Yi, S | 1 |
| Brown, LC; Burke, L; Downing, A; Fenton, H; Fuller, H; Hull, MA; Loadman, PM; Race, AD; Rees, CJ; Williams, EA | 1 |
| Brown, LC; Davies, JR; Downing, A; Fuller, H; Harland, M; Hull, MA; Loadman, PM; Mell, T; Minihane, AM; Race, AD; Rees, CJ; Saleh, RNM; Williams, EA | 1 |
22 review(s) available for aspirin and eicosapentaenoic acid
| Article | Year |
|---|---|
Studies on the biological balance between thromboxanes and prostacyclins in relation to the platelet-vessel wall interaction.
Topics: Adolescent; Adult; Aged; Aspirin; Bleeding Time; Blood Platelets; Blood Vessels; Child; Diabetes Mellitus; Eicosapentaenoic Acid; Epoprostenol; Fatty Acids, Unsaturated; Humans; Hydrocortisone; Male; Middle Aged; Phosphodiesterase Inhibitors; Platelet Aggregation; Prostaglandin Endoperoxides; Prostaglandins; Thromboxanes | 1982 |
[Blood platelets and prostaglandins].
Topics: Aspirin; Blood Platelets; Eicosapentaenoic Acid; Epoprostenol; Fatty Acids, Unsaturated; Humans; SRS-A | 1983 |
Mechanism of anti-proliferative action of eicosapentaenoic acid (EPA) in vascular cell growth: its effect on signal transduction system.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Arteriosclerosis; Arteriosclerosis Obliterans; Aspirin; Cell Division; Cells, Cultured; Clinical Trials as Topic; Eicosanoids; Eicosapentaenoic Acid; Epoprostenol; Fibrinolytic Agents; Growth Inhibitors; Hemostasis; Humans; Hypolipidemic Agents; Muscle, Smooth, Vascular; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Signal Transduction; Thrombophilia; Thrombosis; Thromboxane A2 | 1997 |
Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Humans; Inflammation | 2004 |
Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Humans; Inflammation Mediators; Neuroprotective Agents | 2005 |
Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers.
Topics: Animals; Aspirin; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Humans; Inflammation; Neuroprotective Agents | 2004 |
The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: novel oxygenase products from omega-3 polyunsaturated fatty acids.
Topics: Animals; Aspirin; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Humans; Oxygenases | 2005 |
Lipoxins and new lipid mediators in the resolution of inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acids; Aspirin; Disease Models, Animal; Docosahexaenoic Acids; Eicosapentaenoic Acid; Humans; Inflammation; Lipid Metabolism; Lipoxins; Signal Transduction | 2006 |
Cell-cell interaction in the transcellular biosynthesis of novel omega-3-derived lipid mediators.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Line, Tumor; Docosahexaenoic Acids; Eicosapentaenoic Acid; Humans; Inflammation | 2006 |
Novel chemical mediators in the resolution of inflammation: resolvins and protectins.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; CD59 Antigens; Complement Inactivating Agents; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Humans; Inflammation; Neuroprotective Agents | 2006 |
New perspectives on aspirin and the endogenous control of acute inflammatory resolution.
Topics: Adaptor Proteins, Signal Transducing; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Docosahexaenoic Acids; Eicosapentaenoic Acid; Endothelial Cells; Fatty Acids, Omega-3; Humans; Inflammation; Leukocytes; Lipoxins; Lipoxygenase; Models, Biological; Nitric Oxide; Receptors, Aryl Hydrocarbon; Signal Transduction | 2006 |
[Resolvins: new derivates of fatty acids, polyunsaturated (omega-3) with therapeutic potential in inflammatory intestinal diseases].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Humans; Inflammatory Bowel Diseases; Treatment Outcome | 2006 |
Control of inflammation and periodontitis.
Topics: Alveolar Bone Loss; Animals; Anti-Inflammatory Agents; Aspirin; Biofilms; Bone Regeneration; Disease Susceptibility; Eicosapentaenoic Acid; Humans; Inflammation; Lipoxins; Periodontitis | 2007 |
Is Alzheimer's disease a synaptic disorder?
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Docosahexaenoic Acids; Eicosapentaenoic Acid; Feeding Behavior; Humans; Synapses | 2008 |
Resolvins: Current understanding and future potential in the control of inflammation.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Docosahexaenoic Acids; Eicosapentaenoic Acid; Humans; Inflammation; Lipoxins; Molecular Structure; Signal Transduction; Structure-Activity Relationship | 2009 |
Omega-3 PUFA derived anti-inflammatory lipid mediator resolvin E1.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cell Adhesion Molecules; Docosahexaenoic Acids; Eicosapentaenoic Acid; Exudates and Transudates; Fatty Acids, Omega-3; Humans; Inflammation; Mononuclear Phagocyte System; Phagocytes | 2009 |
COX-2, aspirin and metabolism of arachidonic, eicosapentaenoic and docosahexaenoic acids and their physiological and clinical significance.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Cyclooxygenase 2; Docosahexaenoic Acids; Eicosapentaenoic Acid; Humans | 2016 |
[Pharmacological therapy of age-related macular degeneration based on etiopathogenesis].
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Aspirin; Bosentan; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infliximab; Lutein; Macular Degeneration; Melatonin; PPAR gamma; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System; Resveratrol; Stilbenes; Sulfonamides; Trimetazidine; Tumor Necrosis Factor-alpha; Ubiquinone; Vitamin D; Xanthophylls | 2015 |
Combination of aspirin with essential fatty acids is superior to aspirin alone to prevent or ameliorate sepsis or ARDS.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Drug Therapy, Combination; Eicosapentaenoic Acid; Humans; Respiratory Distress Syndrome; Sepsis | 2016 |
Modulation of microRNAs by aspirin in cardiovascular disease.
Topics: Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Docosahexaenoic Acids; Drug Resistance; Eicosapentaenoic Acid; Endothelial Cells; Humans; Lipoxins; MicroRNAs; Myocytes, Smooth Muscle; Platelet Aggregation Inhibitors | 2020 |
The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Eicosapentaenoic Acid; Hemorrhage; Humans; Models, Economic; Randomized Controlled Trials as Topic; Rivaroxaban; Time Factors; Treatment Outcome | 2020 |
Aspirin and omega-3 polyunsaturated fatty acid use and their interaction in cardiovascular diseases and colorectal adenomas.
Topics: Adenoma; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Humans | 2022 |
19 trial(s) available for aspirin and eicosapentaenoic acid
| Article | Year |
|---|---|
Effect of eicosapentaenoic acid on restenosis rate, clinical course and blood lipids in patients after percutaneous transluminal coronary angioplasty.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Disease; Dipyridamole; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Humans; Lipids; Male; Middle Aged; Postoperative Care; Recurrence | 1990 |
Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids.
Topics: Angioplasty, Balloon; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Angiography; Coronary Disease; Coronary Vessels; Diet; Dipyridamole; Eicosapentaenoic Acid; Fatty Acids; Humans; Male; Middle Aged; Random Allocation; Recurrence; Time Factors | 1988 |
Effect of low-dose aspirin in combination with stable fish oil on whole blood production of eicosanoids.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aspirin; Drug Interactions; Eicosanoids; Eicosapentaenoic Acid; Fish Oils; Humans; Leukotriene B4; Middle Aged; Thromboxane B2 | 2001 |
Efficacy of n-3 polyunsaturated fatty acids after myocardial infarction: results of GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Diet; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Recurrence; Stroke; Vitamin E | 2001 |
Recurrent miscarriage associated with antiphospholipid antibodies: prophylactic treatment with low-dose aspirin and fish oil derivates.
Topics: Abortion, Habitual; Adult; Antiphospholipid Syndrome; Aspirin; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Drug Combinations; Eicosapentaenoic Acid; Female; Humans; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy Outcome; Prospective Studies; Thrombosis | 2005 |
Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arteriovenous Shunt, Surgical; Aspirin; Clinical Protocols; Docosahexaenoic Acids; Double-Blind Method; Drug Combinations; Eicosapentaenoic Acid; Humans; Kidney Failure, Chronic; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Thrombosis; Vascular Patency | 2009 |
Adjunctive treatment of chronic periodontitis with daily dietary supplementation with omega-3 Fatty acids and low-dose aspirin.
Topics: Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Periodontitis; Combined Modality Therapy; Dental Plaque Index; Dental Scaling; Dietary Supplements; Docosahexaenoic Acids; Double-Blind Method; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Follow-Up Studies; Gingival Hemorrhage; Humans; Male; Matrix Metalloproteinase 8; Middle Aged; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Placebos; RANK Ligand; Root Planing; Saliva; Treatment Outcome | 2010 |
A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized cont
Topics: Adenoma; Aged; Anticarcinogenic Agents; Aspirin; Biomarkers, Tumor; Clinical Protocols; Colonoscopy; Colorectal Neoplasms; Double-Blind Method; Drug Therapy, Combination; Eicosapentaenoic Acid; England; Female; Humans; Male; Middle Aged; Predictive Value of Tests; Research Design; Risk Assessment; Risk Factors; Sample Size; State Medicine; Time Factors; Treatment Outcome | 2013 |
N-3 polyunsaturated fatty acids do not influence the efficacy of dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention.
Topics: Aged; Angina, Stable; Aspirin; Blood Platelets; Clopidogrel; Docosahexaenoic Acids; Drug Combinations; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Poland; Prospective Studies; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
The effects of aspirin on platelet function and lysophosphatidic acids depend on plasma concentrations of EPA and DHA.
Topics: Adult; Aged; Aspirin; Blood Platelets; Diabetes Mellitus, Type 2; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Female; Humans; Lysophospholipids; Male; Middle Aged; Platelet Aggregation Inhibitors | 2015 |
The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Central Venous Catheters; Docosahexaenoic Acids; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fish Oils; Humans; Kidney Failure, Chronic; Platelet Aggregation Inhibitors; Postoperative Complications; Renal Dialysis; Renal Insufficiency, Chronic; Thrombosis | 2015 |
Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Australia; Comorbidity; Docosahexaenoic Acids; Double-Blind Method; Drug Combinations; Eicosapentaenoic Acid; Female; Fibrinolytic Agents; Graft Occlusion, Vascular; Humans; Malaysia; Male; Middle Aged; New Zealand; Prevalence; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Severity of Illness Index; Thrombosis; Time Factors; Treatment Outcome; United Kingdom; Vascular Patency | 2016 |
Specialized proresolving lipid mediators in humans with the metabolic syndrome after n-3 fatty acids and aspirin.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Combined Modality Therapy; Cyclooxygenase Inhibitors; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Fish Oils; Humans; Immunity, Innate; Male; Metabolic Syndrome; Middle Aged; Postmenopause; Tablets, Enteric-Coated; Western Australia; Young Adult | 2015 |
Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling.
Topics: Aged; Aspirin; Biomarkers; Coronary Disease; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Gene Expression Regulation; Humans; Lipid Metabolism; Lipoxins; Male; Middle Aged; Platelet Aggregation Inhibitors | 2016 |
Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial.
Topics: Adenoma; Aged; Anticarcinogenic Agents; Aspirin; Colonoscopy; Colorectal Neoplasms; Double-Blind Method; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Humans; Male; Middle Aged | 2018 |
The effects of aspirin and N-3 fatty acids on telomerase activity in adults with diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Diabetes Mellitus, Type 2; Docosahexaenoic Acids; Eicosapentaenoic Acid; Female; Humans; Male; Middle Aged; New York; Telomerase; Telomere Homeostasis; Treatment Outcome | 2020 |
Aspirin and omega-3 fatty acid status interact in the prevention of cardiovascular diseases in Framingham Heart Study.
Topics: Aged; Arachidonic Acid; Aspirin; Cardiovascular Diseases; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Female; Humans; Longitudinal Studies; Male; Middle Aged; Treatment Outcome | 2021 |
Plasma and rectal mucosal oxylipin levels during aspirin and eicosapentaenoic acid treatment in the seAFOod polyp prevention trial.
Topics: Aspirin; Eicosapentaenoic Acid; Humans; Lipoxins; Mucous Membrane; Oxylipins | 2023 |
Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Polyps; Colorectal Neoplasms; Cyclooxygenase 2; Eicosapentaenoic Acid; Genes, p53; Humans; Lipoxygenase; Oxylipins; Polymorphism, Single Nucleotide; Risk Reduction Behavior; Tumor Suppressor Protein p53 | 2023 |
37 other study(ies) available for aspirin and eicosapentaenoic acid
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Anti-platelet therapy in diabetic and non-diabetic progressive renal failure.
Topics: Aspirin; Blood Pressure; Creatinine; Diabetic Nephropathies; Dipyridamole; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Fish Oils; Glomerular Filtration Rate; Hemostasis; Humans; Hypertension; Kidney Failure, Chronic; Male; Platelet Aggregation Inhibitors; Proteinuria | 1992 |
Aspirin-induced decline in prostacyclin production in patients with coronary artery disease is due to decreased endoperoxide shift. Analysis of the effects of a combination of aspirin and n-3 fatty acids on the eicosanoid profile.
Topics: Aged; Arachidonic Acid; Aspirin; Coronary Disease; Eicosanoids; Eicosapentaenoic Acid; Epoprostenol; Female; Fish Oils; Humans; Male; Middle Aged; Phospholipids; Prostaglandin Endoperoxides; Thromboxanes | 1991 |
Eicosapentaenoic acid interferes with U46619-stimulated formation of inositol phosphates in washed rabbit platelets.
Topics: Animals; Aspirin; Blood Platelets; Eicosapentaenoic Acid; In Vitro Techniques; Inositol Phosphates; Phospholipids; Platelet Aggregation; Platelet Aggregation Inhibitors; Prostaglandin Endoperoxides, Synthetic; Rabbits | 1989 |
[Medical treatment of peripheral arterial diseases].
Topics: Aspirin; Eicosapentaenoic Acid; Fibrinolytic Agents; Humans; Intermittent Claudication; Physical Exertion; Vasodilator Agents | 1987 |
Effects of arachidonic acid on the metabolism of eicosapentaenoic acid in washed human platelets.
Topics: Arachidonic Acid; Arachidonic Acids; Aspirin; Blood Platelets; Carbon Radioisotopes; Eicosapentaenoic Acid; Humans; Hydroxyeicosatetraenoic Acids; Indomethacin; Kinetics; Prostaglandins G | 1985 |
Hemostatic factors and renin in Greenland Eskimos on a high eicosapentaenoic acid intake. Results of the Fifth UmanaK Expedition.
Topics: Adult; Animals; Antithrombin III; Aspirin; Bleeding Time; Blood Platelets; Blood Pressure; Denmark; Eicosapentaenoic Acid; Feeding Behavior; Female; Fishes; Greenland; Hemostasis; Humans; Inuit; Lipids; Male; Prostaglandins; Renin | 1986 |
Effects of a fish oil enriched diet on aspirin intolerant asthmatic patients: a pilot study.
Topics: Adult; Aged; Albuterol; Aspirin; Asthma; Dietary Fats, Unsaturated; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Fatty Acids; Fatty Acids, Unsaturated; Female; Fish Oils; Humans; Male; Middle Aged; Peak Expiratory Flow Rate; Thromboxane B2 | 1988 |
Effects of 11-week increases in dietary eicosapentaenoic acid on bleeding time, lipids, and platelet aggregation.
Topics: Adult; Arteriosclerosis; Aspirin; Bleeding Time; Blood Platelets; Diet; Eicosanoic Acids; Eicosapentaenoic Acid; Fatty Acids; Fatty Acids, Unsaturated; Humans; Male; Phospholipids; Platelet Aggregation; Platelet Function Tests; Time Factors | 1981 |
Effects of acetylsalicylic acid on platelet aggregation before and during increase in dietary eicosapentaenoic acid.
Topics: Adenosine Diphosphate; Adult; Animals; Aspirin; Blood Platelets; Collagen; Dietary Fats; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Fishes; Humans; Male; Platelet Aggregation; Prostaglandins | 1983 |
Reduction in human neutrophil superoxide anion generation by n-3 polyunsaturated fatty acids: role of cyclooxygenase products and endothelium-derived relaxing factor.
Topics: Arachidonic Acid; Arginine; Aspirin; Depression, Chemical; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Humans; Indomethacin; Neutrophils; Nitric Oxide; omega-N-Methylarginine; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Respiratory Burst; Superoxides | 1994 |
Docosahexaenoic and eicosapentaenoic acids inhibit human lymphoproliferative responses in vitro but not the expression of T cell surface activation markers.
Topics: Adult; Antigens, Differentiation, T-Lymphocyte; Aspirin; Cells, Cultured; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Humans; Immunosuppressive Agents; Interleukin-2; Kinetics; Lymphocyte Activation; Phytohemagglutinins; Vitamin E | 1996 |
Suppression of the hypersensitive response in potato by acetyl salicylic acid.
Topics: Antifungal Agents; Arachidonic Acid; Aspirin; Eicosapentaenoic Acid; Phytophthora; Plant Diseases; Solanum tuberosum; Terpenes | 1996 |
Effect of n-3 fatty acids on VLDL production by hepatocytes is mediated through prostaglandins.
Topics: Animals; Apolipoproteins B; Aspirin; Diethylcarbamazine; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Indomethacin; Leucine; Lipoproteins, VLDL; Liver; Male; Palmitic Acid; Prostaglandins; Rats; Rats, Sprague-Dawley; Tritium | 1997 |
Changes in prostacyclin, thromboxane A2 and F2-isoprostanes, and influence of eicosapentaenoic acid and antiplatelet agents in patients with hypertension and hyperlipidemia.
Topics: Aspirin; Dinoprost; Dipyridamole; Eicosapentaenoic Acid; Epoprostenol; Humans; Hyperlipidemias; Hypertension; Platelet Aggregation Inhibitors; Thromboxane A2; Ticlopidine | 1999 |
Formation of endogenous "antiinflammatory" lipid mediators by transcellular biosynthesis. Lipoxins and aspirin-triggered lipoxins inhibit neutrophil recruitment and vascular permeability.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acids; Aspirin; Biopsy, Needle; Capillary Permeability; Depression, Chemical; Disease Models, Animal; Ear Diseases; Ear, External; Eicosapentaenoic Acid; Inflammation; Inflammation Mediators; Lipids; Mice; Mice, Inbred BALB C; Mice, Knockout; Neutrophil Infiltration; Peritonitis | 2000 |
Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Line; Cells, Cultured; Cyclooxygenase 2; Eicosapentaenoic Acid; Endothelium, Vascular; Fatty Acids, Omega-3; Humans; In Vitro Techniques; Indomethacin; Inflammation; Isoenzymes; Male; Membrane Proteins; Mice; Mice, Inbred Strains; Microcirculation; Microsomes; Neutrophils; Prostaglandin-Endoperoxide Synthases; Receptors, Leukotriene B4; Recombinant Proteins; Transfection; Tumor Necrosis Factor-alpha; Umbilical Veins | 2000 |
Arachidonic acid reduces the stress response of gilthead seabream Sparus aurata L.
Topics: Analysis of Variance; Animals; Aquaculture; Arachidonic Acid; Aspirin; Chlorides; Confined Spaces; Diet; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Female; Gills; Kidney; Male; Sea Bream; Sodium; Sodium-Potassium-Exchanging ATPase; Stress, Physiological; Water-Electrolyte Balance | 2004 |
Specific effect of arachidonic acid on inducible nitric oxide synthase mRNA expression in human osteoblastic cells.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Arachidonic Acid; Aspirin; Cell Line, Tumor; Cyclooxygenase Inhibitors; Cytokines; Eicosapentaenoic Acid; Enzyme Activation; Genistein; Humans; Naphthalenes; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Oleic Acid; Osteoblasts; Protein Kinase C; Protein-Tyrosine Kinases; RNA, Messenger | 2005 |
Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis.
Topics: Animals; Aspirin; Colitis, Ulcerative; DNA Primers; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation; Immunoglobulin G; Interleukin-12; Interleukin-12 Subunit p40; Leukocytes; Mice; Mice, Inbred BALB C; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Peroxidase; Protein Subunits; Reverse Transcriptase Polymerase Chain Reaction; Trinitrobenzenesulfonic Acid; Tumor Necrosis Factor-alpha | 2005 |
Asymmetric acetylation of the cyclooxygenase-2 homodimer by aspirin and its effects on the oxygenation of arachidonic, eicosapentaenoic, and docosahexaenoic acids.
Topics: Acetylation; Arachidonic Acid; Aspirin; Base Sequence; Chromatography, Liquid; Chromatography, Thin Layer; Cyclooxygenase 2; Diclofenac; Dimerization; DNA Primers; Docosahexaenoic Acids; Eicosapentaenoic Acid; Humans; Mutagenesis; Oxygen; Tandem Mass Spectrometry | 2010 |
Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis.
Topics: Adaptor Proteins, Signal Transducing; Aged; Anti-Inflammatory Agents; Aspirin; Atherosclerosis; Blotting, Western; Case-Control Studies; Cell Survival; Chemotaxis; Eicosapentaenoic Acid; Female; Flow Cytometry; Humans; Immunoenzyme Techniques; Lipoxins; Male; Middle Aged; Muscle, Smooth, Vascular; Peripheral Arterial Disease; Phenotype; Phosphorylation; Platelet-Derived Growth Factor; Prospective Studies; Receptors, Chemokine; Receptors, Platelet-Derived Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Saphenous Vein | 2010 |
Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Aspirin; Cyclooxygenase 2; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fish Oils; Humans; Inflammation; Leukocytes; Mice; Molecular Structure; Recombinant Proteins; Stereoisomerism | 2011 |
The assessment of risk for gastrointestinal injury with anticoagulant and antiplatelet drugs: the possible beneficial effect of eicosapentaenoic Acid for the risk of gastrointestinal injury.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Eicosapentaenoic Acid; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Protective Agents; Retrospective Studies; Risk Assessment; Ticlopidine; Warfarin | 2013 |
Ratio of eicosapentaenoic acid to arachidonic acid is a critical risk factor for acute coronary syndrome in middle-aged older patients as well as younger adult patients.
Topics: Acute Coronary Syndrome; Adult; Aged; Angiotensin Receptor Antagonists; Arachidonic Acid; Aspirin; Calcium Channel Blockers; Cholesterol, HDL; Coronary Angiography; Drugs, Chinese Herbal; Eicosapentaenoic Acid; Eleutherococcus; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Multivariate Analysis; Risk Factors; Smoking | 2014 |
Effects of eicosapentaenoic acid on platelet function in patients taking long-term aspirin following coronary stent implantation.
Topics: Administration, Oral; Aspirin; Blood Platelets; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Follow-Up Studies; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Revascularization; Platelet Aggregation; Retrospective Studies; Stents; Time Factors | 2014 |
Aging delays resolution of acute inflammation in mice: reprogramming the host response with novel nano-proresolving medicines.
Topics: Aging; Animals; Aspirin; Autacoids; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Humans; Inflammation; Inflammation Mediators; Leukocytes, Mononuclear; Macrophages; Male; Metabolomics; Mice; Mice, Inbred BALB C; Nanomedicine; Peritonitis; Principal Component Analysis; Zymosan | 2014 |
Resolvin E1 normalizes contractility, Ca2+ sensitivity and smooth muscle cell migration rate in TNF-α- and IL-6-pretreated human pulmonary arteries.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Calcium; Cell Movement; Docosahexaenoic Acids; Eicosapentaenoic Acid; Humans; Hypertension, Pulmonary; In Vitro Techniques; Indoles; Inflammation Mediators; Interleukin-6; Lipoxygenase Inhibitors; Matrix Metalloproteinase 9; Models, Biological; Monoglycerides; Myocytes, Smooth Muscle; Pulmonary Artery; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vasoconstriction | 2015 |
Aspirin and Eicosapentaenoic Acid May Arrest Progressive IgA Nephropathy: A Potential Alternative to Immunosuppression.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Glomerulonephritis, IGA; Humans; Male; Middle Aged; Young Adult | 2015 |
Effects of aspirin in combination with EPA and DHA on HDL-C cholesterol and ApoA1 exchange in individuals with type 2 diabetes mellitus.
Topics: Adult; Aged; Apolipoprotein A-I; Aspirin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Eicosapentaenoic Acid; Female; Humans; Male; Middle Aged; Triglycerides | 2017 |
Variations in the eicosapentaenoic acid-arachidonic acid ratio associated with age in acute myocardial infarction patients undergoing primary percutaneous coronary intervention.
Topics: Age Factors; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Biomarkers; Eicosapentaenoic Acid; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Retrospective Studies; Risk Factors; ROC Curve | 2019 |
Take a pill for no more polyps: is it that simple?
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Double-Blind Method; Eicosapentaenoic Acid; Humans; Polyps | 2018 |
No risk reduction of colorectal adenoma with aspirin or eicosapentaenoic acid.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Double-Blind Method; Eicosapentaenoic Acid; Humans | 2019 |
An Abstract Provides "seAFOod" for Thought.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Double-Blind Method; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Humans | 2019 |
Eicosapentaenoic acid and aspirin for colorectal adenomas.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Double-Blind Method; Eicosapentaenoic Acid; Humans; Polyps | 2019 |
Add-On Therapies in Cardiovascular Disease: Reviewing ICER's Report and the Potential Effect on Payers.
Topics: Age Factors; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Drug Utilization Review; Early Termination of Clinical Trials; Eicosapentaenoic Acid; Hemorrhage; Humans; Medicare; Models, Economic; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome; United States | 2020 |
Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acid.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Celecoxib; Cell Line, Tumor; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Resistance, Neoplasm; Eicosapentaenoic Acid; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Xenograft Model Antitumor Assays | 2021 |